

Press release
Uppsala, Sweden, February 13, 2007

Gyros completes five new sales of its Gyrolab[®] protein quantification platform

Uppsala, Sweden, 13 February, 2007. Gyros announced today that it has completed the separate sales of five Gyrolab[®] microfluidic system platforms to Merck, Biogen-Idec and a third, unnamed company, all in the USA, and to NovImmune and Serono in Europe.

Gyros microfluidic platform consists of Gyrolab Bioaffy[®] compact disk (CD) microlaboratories (facilitating miniaturized and integrated protein quantification applications) and Gyrolab Workstation (a fully automated system for running Gyrolab Bioaffy CDs). Together they provide a simple to use, precisely controlled solution for processing hundreds of samples in parallel at nanoliter scale. Scientists are able to use immunoassays with a very broad measurement range to generate more information from less sample, improving both productivity and efficiency.

Commenting on the recent sales, Gyros CEO, Jan Würtz, said, "2006 was a successful year for Gyros. Following sales earlier in 2006 to CAT and AstraZeneca, these five new sales mean that we are really starting to extend our customer base. We will be looking to continue this trend through 2007, as more and more companies recognize that our microfluidic technology can provide them with significant advantages over traditional methods, like ELISA."

About Gyros AB

Gyros is the leader in the miniaturization and integration of laboratory applications through its proprietary microfluidics platform, Gyrolab CD (compact disc) microlaboratory. Gyros delivers simple to use, precisely controlled solutions for processing hundreds of samples in parallel, generating more information from less sample and improving lab productivity and efficiency.

Application-specific microlaboratories use a modular design offering the potential to run different applications on a single instrument and to create customized solutions. The company is currently focused on two market segments: quantitative protein analysis for research, drug discovery and development applications; and, *in vitro* diagnostics for medical applications. Gyros has 50 employees working at its headquarters and European sales office in Uppsala, Sweden and its sales office in the USA.

For further information, visit www.gyros.com or contact:

Jan Würtz, President and CEO, Gyros AB

Tel: +46 (0)18 566 400

Mobile: +46 (0)70 592 5670

jan.wurtz@gyros.com

Christina Burtsoff Asp, VP Marketing, Gyros AB

Tel: +46 (0)18 566 404

Mobile: +46 (0)70 666 1642

christina.asp@gyros.com

Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.
